logo
Plus   Neg
Share
Email

Moderna Says First Participant Dosed In Phase 1/2 Study Of COVID-19 Vaccine In Japan

Moderna Inc. (MRNA) said Thursday that the first participant has been dosed in the Phase 1/2 study of the company's vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co.

TAK-919 is Takeda's development code for Moderna's COVID-19 vaccine candidate.

According to the company, the placebo-controlled Phase 1/2 study will evaluate the safety and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart.

Takeda plans to enroll 200 participants aged 20 years and above in Japan. Each participant will be assigned to receive a placebo or a 100 µg dose at both vaccinations. Participants will be followed through 12 months after the second vaccination, Moderna said. .

Previously, the companies said that Takeda will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate starting in the first half of 2021.

Moderna received authorization for its COVID-19 vaccine from regulatory authorities in the United States, Canada, Israel, the European Union, the United Kingdom and Switzerland. Additional authorizations are currently under review in other countries and by the World Health Organization.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Australian government has passed the newly amended Media Bargaining Code in the parliament which requires technology giants Facebook and Google to pay for local Australian news content that is shared on their platforms. Regeneron Pharmaceuticals, Inc. (REGN) Thursday said it stopped enrollment into the placebo group for its Phase 3 trial of REGEN-COV in non-hospitalised patients with COVID-19 as per the recommendations from the Independent Data Monitoring Committee or IDMC. According to the company, the IDMC found... Moderna Inc. (MRNA) Thursday reported a fourth-quarter net loss that widened from last year. But quarterly revenues surged from the previous year, driven by increases in grant revenue and product sales. The company raised its 2021 COVID-19 vaccine manufacturing plan.
Follow RTT